Covid vaccine: Dr. Scott Gottlieb expects shortages to last through next week

Dr. Scott Gottlieb advised CNBC on Friday he expects a scarcity of Covid-19 vaccine doses to proceed previous next week, even when the Food and Drug Administration points emergency use authorization for Moderna's vaccine.

"I've talked to hospitals. They're vaccinating far fewer health-care providers than what they could be because they just don't have the doses available," the previous FDA chief and Pfizer board member stated on "Squawk Box." "I don't think that they're going to catch up next week even after the Moderna doses ship and you start having more supply in the channel."

Suresh Gunasekaran, CEO of University of Iowa Hospitals & Clinics, painted the same account to CNBC.

"We received one Pfizer batch earlier this week with 975 doses, and we can report that we concluded vaccinating 975 people yesterday," Gunasekaran stated Friday on "Squawk on the Street." "To be perfectly honest, if we needed to vaccinate double or triple that amount in the last few days, we could have. Really the availability of vaccine was really our rate limiting step."

The U.S. started administering pictures to health-care staff Monday, simply days after Pfizer and BioNTech's Covid-19 vaccine acquired restricted regulatory approval. However, confusion has arisen in latest days as some governors throughout the nation have stated they now anticipate to obtain fewer doses than anticipated within the coming weeks.

The Department of Health and Human Services has pushed again on these options, telling CNBC in an announcement that studies that "jurisdictions' allocations are being reduced are incorrect." The assertion added, "As was done with the initial shipments of Pfizer vaccine, jurisdictions will receive vaccine at different sites over several days."

In an announcement Thursday, Pfizer stated its manufacturing has not skilled any disruptions regardless of claims from Republican Florida Gov. Ron DeSantis earlier this week that the drug firm has had a manufacturing subject main to dose shortages.

"This week, we successfully shipped all 2.9 million doses that we were asked to ship by the U.S. Government to the locations specified by them," Pfizer stated. "We have millions more doses sitting in our warehouse but, as of now, we have not received any shipment instructions for additional doses."

The U.S. authorities has stated it plans to ship 2 million doses of Pfizer's vaccine next week. Moderna's vaccine may obtain emergency approval as quickly as Friday, and U.S. officers have stated that slightly below 6 million doses of its vaccine may very well be shipped next week.

Gottlieb advised CNBC he believes a number of the confusion round accessible provide of Pfizer's vaccine may very well be stemming from authorities considerations concerning the logistics community. He stated there stands out as the need to mood the provision of Pfizer's vaccine within the system to be certain that the distribution community can deal with it and doses don't pile up anyplace.

"I think they should be taking some risk and leaning forward, trying to get more doses in people's arms, both Moderna and Pfizer," Gottlieb stated, noting the present depth of the U.S. epidemic. "I think getting as much protective immunity out into the population as possible is very important right now."

Hospital staff and residents of long-term care services are receiving precedence within the preliminary wave of vaccine distribution. "I think they could have pushed out more vaccine through the hospitals this month than what they're doing. We could vaccinated many more people," Gottlieb stated.

How Moderna's Covid vaccine distribution shall be completely different than Pfizer'sSquawk Box

Disclosure: Scott Gottlieb is a CNBC contributor and is a member of the boards of Pfizer, genetic testing start-up Tempus and biotech firm Illumina. Pfizer has a producing settlement with Gilead for remdesivir. Gottlieb additionally serves as co-chair of Norwegian Cruise Line Holdings′ and Royal Caribbean's "Healthy Sail Panel." 

Source

About The Author

Related posts